NCT05048212 2026-03-02
A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Recruiting
M.D. Anderson Cancer Center
Neonc Technologies, Inc.
Melanoma Institute Australia
InSightec
Stanford University
Herlev Hospital